Early stage life science companies still developing their technologies can fall into a gap: too expensive to be supported by more grants or angel investments yet not far enough along to secure venture capital interest.
In the worst economy in generations, their funding challenges are more pronounced. But the first quarter saw several companies in North Carolina’s Research Triangle draw venture capital investments for continued development of pharmaceutical products and medical technologies. Among them, antiviral company Chimerix raised $45 million; nanotechology company Liquidia Technologies raised $10 million; and diagnostic technology firm Advanced Animal Diagnostics raised $11 million.
To read the full, original article click on this link: RTP venture capital climate improved in Q1 but biotechs still clamor for cash
Author:
